Cargando…
One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA
BACKGROUND: Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease, with between 10 and 50% of patients with these conditions having cachexia. Curre...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Just Medical Media Limited
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130358/ https://www.ncbi.nlm.nih.gov/pubmed/25126097 http://dx.doi.org/10.7573/dic.212265 |
_version_ | 1782330318701723648 |
---|---|
author | Arthur, Susan Tsivitse Noone, Joshua M Van Doren, Bryce A Roy, Debosoree Blanchette, Christopher M |
author_facet | Arthur, Susan Tsivitse Noone, Joshua M Van Doren, Bryce A Roy, Debosoree Blanchette, Christopher M |
author_sort | Arthur, Susan Tsivitse |
collection | PubMed |
description | BACKGROUND: Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease, with between 10 and 50% of patients with these conditions having cachexia. Currently there is little research into cachexia and our objective is to characterize cachexia patients, their healthcare utilization, and associated hospitalization costs. Given the increasing prevalence of chronic diseases, it is important to better understand cachexia so that the condition can be better diagnosed and managed. METHODS: We utilized one year (2009) of the Nationwide Inpatient Sample (NIS). The NIS represents all inpatient stays at a random 20% sample of all hospitals within the United States. We grouped cachexia individuals by primary or secondary discharge diagnosis and then compared those with cachexia to all others in terms of length of stay (LOS) and total cost. Finally we looked into factors predicting increased LOS using a negative binomial model. RESULTS: We estimated US prevalence for cachexia-related inpatient admissions at 161,898 cases. Cachexia patients were older, with an average age of 67.95 versus 48.10 years in their non-cachexia peers. Hospitalizations associated with cachexia had an increased LOS compared to non-cachexia patients (6 versus 3 days), with average costs per stay $4641.30 greater. Differences were seen in loss of function (LOF) with cachexia patients, mostly in the major LOF category (52.60%), whereas non-cachexia patients were spread between minor, moderate, and major LOF (36.28%, 36.11%, and 21.26%, respectively). Significant positive predictors of increased LOS among cachexia patients included urban hospital (IRR=1.21, non-teaching urban; IRR=1.23, teaching urban), having either major (IRR=1.41) or extreme (IRR=2.64) LOF, and having a primary diagnosis of pneumonia (IRR=1.15). CONCLUSION: We have characterized cachexia and seen it associated with increased length of stay, increased cost, and more severe loss of function in patients compared to those without cachexia. |
format | Online Article Text |
id | pubmed-4130358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Just Medical Media Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-41303582014-08-14 One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA Arthur, Susan Tsivitse Noone, Joshua M Van Doren, Bryce A Roy, Debosoree Blanchette, Christopher M Drugs Context Original Research BACKGROUND: Cachexia is a condition characterized as a loss in body mass or metabolic dysfunction and is associated with several prevalent chronic health conditions including many cancers, COPD, HIV, and kidney disease, with between 10 and 50% of patients with these conditions having cachexia. Currently there is little research into cachexia and our objective is to characterize cachexia patients, their healthcare utilization, and associated hospitalization costs. Given the increasing prevalence of chronic diseases, it is important to better understand cachexia so that the condition can be better diagnosed and managed. METHODS: We utilized one year (2009) of the Nationwide Inpatient Sample (NIS). The NIS represents all inpatient stays at a random 20% sample of all hospitals within the United States. We grouped cachexia individuals by primary or secondary discharge diagnosis and then compared those with cachexia to all others in terms of length of stay (LOS) and total cost. Finally we looked into factors predicting increased LOS using a negative binomial model. RESULTS: We estimated US prevalence for cachexia-related inpatient admissions at 161,898 cases. Cachexia patients were older, with an average age of 67.95 versus 48.10 years in their non-cachexia peers. Hospitalizations associated with cachexia had an increased LOS compared to non-cachexia patients (6 versus 3 days), with average costs per stay $4641.30 greater. Differences were seen in loss of function (LOF) with cachexia patients, mostly in the major LOF category (52.60%), whereas non-cachexia patients were spread between minor, moderate, and major LOF (36.28%, 36.11%, and 21.26%, respectively). Significant positive predictors of increased LOS among cachexia patients included urban hospital (IRR=1.21, non-teaching urban; IRR=1.23, teaching urban), having either major (IRR=1.41) or extreme (IRR=2.64) LOF, and having a primary diagnosis of pneumonia (IRR=1.15). CONCLUSION: We have characterized cachexia and seen it associated with increased length of stay, increased cost, and more severe loss of function in patients compared to those without cachexia. Just Medical Media Limited 2014-07-31 /pmc/articles/PMC4130358/ /pubmed/25126097 http://dx.doi.org/10.7573/dic.212265 Text en Copyright © 2014 Arthur ST, Noone JM, Van Doren BA, Roy D, Blanchette CM Distributed under the terms of the Creative Commons Attribution License Deed CC BY 3.0. which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No other uses without permission. |
spellingShingle | Original Research Arthur, Susan Tsivitse Noone, Joshua M Van Doren, Bryce A Roy, Debosoree Blanchette, Christopher M One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA |
title | One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA |
title_full | One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA |
title_fullStr | One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA |
title_full_unstemmed | One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA |
title_short | One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA |
title_sort | one-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the usa |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130358/ https://www.ncbi.nlm.nih.gov/pubmed/25126097 http://dx.doi.org/10.7573/dic.212265 |
work_keys_str_mv | AT arthursusantsivitse oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa AT noonejoshuam oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa AT vandorenbrycea oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa AT roydebosoree oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa AT blanchettechristopherm oneyearprevalencecomorbiditiesandcostofcachexiarelatedinpatientadmissionsintheusa |